Iowa 2023-2024 Regular Session

Iowa House Bill HF691 Latest Draft

Bill / Introduced Version Filed 04/06/2023

                            House File 691 - Introduced   HOUSE FILE 691   BY KONFRST , JAMES , STECKMAN ,   CAHILL , LEVIN , NIELSEN ,   KURTH , AMOS JR. , SCHEETZ ,   MADISON , SRINIVAS , WILSON ,   BUCK , CROKEN , BAGNIEWSKI ,   FORBES , BAETH , GAINES ,   ZABNER , GJERDE , JACOBY ,   STAED , KRESSIG , EHLERT ,   ABDUL-SAMAD , B. MEYER ,   OLSON , BROWN-POWERS ,   WESSEL-KROESCHELL ,   SCHOLTEN , WILBURN , MATSON ,   and COOLING   A BILL FOR   An Act relating to the prescribing and dispensing of 1   self-administered hormonal contraceptives. 2   BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA: 3   TLSB 1974YH (5) 90   pf/rh  

  H.F. 691   Section 1. Section 155A.3, Code 2023, is amended by adding 1   the following new subsections: 2   NEW SUBSECTION   . 10A. Department means the department of 3   health and human services. 4   NEW SUBSECTION   . 45A. Self-administered hormonal 5   contraceptive means a self-administered hormonal contraceptive 6   that is approved by the United States food and drug 7   administration to prevent pregnancy. Self-administered 8   hormonal contraceptive includes an oral hormonal contraceptive, 9   a hormonal vaginal ring, and a hormonal contraceptive patch, 10   but does not include any drug intended to induce an abortion as 11   defined in section 146.1. 12   NEW SUBSECTION   . 45B. Standing order means a preauthorized 13   medication order with specific instructions from the medical 14   director of the department to dispense a medication under 15   clearly defined circumstances. 16   Sec. 2. NEW SECTION   . 155A.49 Pharmacist dispensing of 17   self-administered hormonal contraceptives  standing order  18   requirements  limitations of liability. 19   1. a. Notwithstanding any provision of law to the 20   contrary, a pharmacist may dispense a self-administered 21   hormonal contraceptive to a patient pursuant to a standing 22   order established by the medical director of the department in 23   accordance with this section. 24   b. In dispensing a self-administered hormonal contraceptive 25   to a patient under this section, a pharmacist shall comply with 26   all of the following: 27   (1) For an initial dispensing of a self-administered 28   hormonal contraceptive, the pharmacist may dispense up to 29   a twelve-month supply at one time of the self-administered 30   hormonal contraceptive. 31   (2) For any subsequent dispensing of the same 32   self-administered hormonal contraceptive, the pharmacist 33   may dispense up to a twelve-month supply at one time of the 34   self-administered hormonal contraceptive. 35   -1-   LSB 1974YH (5) 90   pf/rh   1/ 10      

  H.F. 691   2. A pharmacist who dispenses a self-administered hormonal 1   contraceptive in accordance with this section shall not 2   require any other prescription drug order authorized by a 3   practitioner prior to dispensing the self-administered hormonal 4   contraceptive to a patient. 5   3. The medical director of the department may establish a 6   standing order authorizing the dispensing of self-administered 7   hormonal contraceptives by a pharmacist who does all of the 8   following: 9   a. Complies with the standing order established pursuant to 10   this section. 11   b. Retains a record of each patient to whom a 12   self-administered hormonal contraceptive is dispensed under 13   this section and submits the record to the department. 14   4. The standing order shall require a pharmacist who 15   dispenses self-administered hormonal contraceptives under this 16   section to do all of the following: 17   a. Complete a standardized training program and continuing 18   education requirements approved by the board in consultation 19   with the board of medicine and the department that are related 20   to prescribing self-administered hormonal contraceptives and 21   include education regarding all contraceptive methods approved 22   by the United States food and drug administration. 23   b. Obtain a completed self-screening risk assessment, 24   approved by the department in collaboration with the board 25   and the board of medicine, from each patient, and verify 26   the identity of each patient prior to dispensing the 27   self-administered hormonal contraceptive to the patient. 28   c. Provide the patient with all of the following: 29   (1) Written information regarding all of the following: 30   (a) The importance of completing an appointment with the 31   patients primary care or womens health care practitioner 32   to obtain preventative care, including but not limited to 33   recommended tests and screenings. 34   (b) The effectiveness and availability of long-acting 35   -2-   LSB 1974YH (5) 90   pf/rh   2/ 10  

  H.F. 691   reversible contraceptives as an alternative to 1   self-administered hormonal contraceptives. 2   (2) A copy of the record of the pharmacists encounter with 3   the patient that includes all of the following: 4   (a) The patients completed self-screening risk assessment. 5   (b) A description of the contraceptive dispensed, or the 6   basis for not dispensing a contraceptive. 7   (3) Patient counseling regarding all of the following: 8   (a) The appropriate administration and storage of the 9   self-administered hormonal contraceptive. 10   (b) Potential side effects and risks of the 11   self-administered hormonal contraceptive. 12   (c) The need for backup contraception. 13   (d) When to seek emergency medical attention. 14   (e) The risk of contracting a sexually transmitted 15   infection or disease, and ways to reduce such a risk. 16   5. The standing order established pursuant to this section 17   shall prohibit a pharmacist who dispenses a self-administered 18   hormonal contraceptive under this section from doing any of the 19   following: 20   a. Requiring a patient to schedule an appointment with 21   the pharmacist for the prescribing or dispensing of a 22   self-administered hormonal contraceptive. 23   b. Dispensing a self-administered hormonal contraceptive to 24   a patient if the results of the self-screening risk assessment 25   completed by a patient pursuant to subsection 4, paragraph 26   b , indicate it is unsafe for the pharmacist to dispense the 27   self-administered hormonal contraceptive to the patient, in 28   which case the pharmacist shall refer the patient to a primary 29   care or womens health care practitioner. 30   6. A pharmacist who dispenses a self-administered hormonal 31   contraceptive and the medical director of the department who 32   establishes a standing order in compliance with this section 33   shall be immune from criminal and civil liability arising from 34   any damages caused by the dispensing, administering, or use of 35   -3-   LSB 1974YH (5) 90   pf/rh   3/ 10  

  H.F. 691   a self-administered hormonal contraceptive or the establishment 1   of the standing order provided that the pharmacist acts 2   reasonably and in good faith. The medical director of the 3   department shall be considered to be acting within the scope 4   of the medical directors office and employment for purposes 5   of chapter 669 in the establishment of a standing order in 6   compliance with this section. 7   7. The department, in collaboration with the board and 8   the board of medicine, and in consideration of the guidelines 9   established by the American congress of obstetricians and 10   gynecologists, shall adopt rules pursuant to chapter 17A to 11   administer this chapter. 12   Sec. 3. Section 514C.19, Code 2023, is amended to read as 13   follows: 14   514C.19 Prescription contraceptive coverage. 15   1. Notwithstanding the uniformity of treatment requirements 16   of section 514C.6 , a group policy ,   or contract , or plan 17   providing for third-party payment or prepayment of health or 18   medical expenses shall not do either of the following   comply 19   as follows : 20   a. Exclude   Such policy, contract, or plan shall not 21   exclude or restrict benefits for prescription contraceptive 22   drugs or prescription contraceptive devices which prevent 23   conception and which are approved by the United States 24   food and drug administration, or generic equivalents 25   approved as substitutable by the United States food and drug 26   administration, if such policy ,   or contract , or plan provides 27   benefits for other outpatient prescription drugs or devices. 28   However, such policy, contract, or plan shall specifically 29   provide for payment including reimbursement for pharmacist   30   consultations, for a self-administered hormonal contraceptive, 31   as prescribed by a practitioner as defined in section   32   155A.3, or as prescribed by standing order and dispensed by a 33   pharmacist pursuant to section 155A.49, including payment for   34   up to an initial twelve-month supply of a self-administered 35   -4-   LSB 1974YH (5) 90   pf/rh   4/ 10                     

  H.F. 691   hormonal contraceptive dispensed at one time and for up to a 1   twelve-month supply of the same self-administered hormonal   2   contraceptive subsequently dispensed at one time. 3   b. Exclude Such policy, contract, or plan shall not exclude 4   or restrict benefits for outpatient contraceptive services 5   which are provided for the purpose of preventing conception if 6   such policy , or contract , or plan provides benefits for other 7   outpatient services provided by a health care professional. 8   2. A person who provides a group policy ,   or contract , or 9   plan providing for third-party payment or prepayment of health 10   or medical expenses which is subject to subsection 1 shall not 11   do any of the following: 12   a. Deny to an individual eligibility, or continued 13   eligibility, to enroll in or to renew coverage under the terms 14   of the policy ,   or contract , or plan because of the individuals 15   use or potential use of such prescription contraceptive drugs 16   or devices, or use or potential use of outpatient contraceptive 17   services. 18   b. Provide a monetary payment or rebate to a covered 19   individual to encourage such individual to accept less than the 20   minimum benefits provided for under subsection 1 . 21   c. Penalize or otherwise reduce or limit the reimbursement 22   of a health care professional because such professional 23   prescribes contraceptive drugs or devices, or provides 24   contraceptive services. 25   d. Provide incentives, monetary or otherwise, to a health 26   care professional to induce such professional to withhold 27   from a covered individual contraceptive drugs or devices, or 28   contraceptive services. 29   3. This section shall not be construed to prevent a 30   third-party payor from including deductibles, coinsurance, or 31   copayments under the policy ,   or contract, or plan as follows: 32   a. A deductible, coinsurance, or copayment for benefits 33   for prescription contraceptive drugs shall not be greater than 34   such deductible, coinsurance, or copayment for any outpatient 35   -5-   LSB 1974YH (5) 90   pf/rh   5/ 10                    

  H.F. 691   prescription drug for which coverage under the policy , or 1   contract , or plan   is provided. 2   b. A deductible, coinsurance, or copayment for benefits for 3   prescription contraceptive devices shall not be greater than 4   such deductible, coinsurance, or copayment for any outpatient 5   prescription device for which coverage under the policy , or 6   contract , or plan is provided. 7   c. A deductible, coinsurance, or copayment for benefits for 8   outpatient contraceptive services shall not be greater than 9   such deductible, coinsurance, or copayment for any outpatient 10   health care services for which coverage under the policy ,   or 11   contract , or plan is provided. 12   4. This section shall not be construed to require a 13   third-party payor under a policy ,   or contract , or plan 14   to provide benefits for experimental or investigational 15   contraceptive drugs or devices, or experimental or 16   investigational contraceptive services, except to the extent 17   that such policy ,   or contract , or plan provides coverage for 18   other experimental or investigational outpatient prescription 19   drugs or devices, or experimental or investigational outpatient 20   health care services. 21   5. This section shall not be construed to limit or otherwise 22   discourage the use of generic equivalent drugs approved by the 23   United States food and drug administration, whenever available 24   and appropriate. This section , when a brand name drug is 25   requested by a covered individual and a suitable generic 26   equivalent is available and appropriate, shall not be construed 27   to prohibit a third-party payor from requiring the covered 28   individual to pay a deductible, coinsurance, or copayment 29   consistent with subsection 3 , in addition to the difference of   30   the cost of the brand name drug less the maximum covered amount 31   for a generic equivalent. 32   6. A person who provides an individual policy ,   or contract , 33   or plan   providing for third-party payment or prepayment of 34   health or medical expenses shall make available a coverage 35   -6-   LSB 1974YH (5) 90   pf/rh   6/ 10                     

  H.F. 691   provision that satisfies the requirements in subsections 1   1 through 5 in the same manner as such requirements are 2   applicable to a group policy ,   or contract , or plan under those 3   subsections. The policy , or contract , or plan shall provide 4   that the individual policyholder may reject the coverage 5   provision at the option of the policyholder. 6   7. a. This section applies to the following classes of 7   third-party payment provider contracts , or policies , or plans 8   delivered, issued for delivery, continued, or renewed in this 9   state on or after July 1, 2000   January 1, 2024 : 10   (1) Individual or group accident and sickness insurance 11   providing coverage on an expense-incurred basis. 12   (2) An individual or group hospital or medical service 13   contract issued pursuant to chapter 509 , 514 , or 514A . 14   (3) An individual or group health maintenance organization 15   contract regulated under chapter 514B . 16   (4) Any other entity engaged in the business of insurance, 17   risk transfer, or risk retention, which is subject to the 18   jurisdiction of the commissioner. 19   (5) A plan established pursuant to chapter 509A for public 20   employees. 21   b. This section shall not apply to accident-only, 22   specified disease, short-term hospital or medical, hospital 23   confinement indemnity, credit, dental, vision, Medicare 24   supplement, long-term care, basic hospital and medical-surgical 25   expense coverage as defined by the commissioner, disability 26   income insurance coverage, coverage issued as a supplement 27   to liability insurance, workers compensation or similar 28   insurance, or automobile medical payment insurance. 29   8.   For the purposes of this section: 30   a.   Self-administered hormonal contraceptive means a 31   self-administered hormonal contraceptive that is approved   32   by the United Sates food and drug administration to prevent 33   pregnancy.   Self-administered hormonal contraceptive includes 34   an oral hormonal contraceptive, a hormonal vaginal ring, and 35   -7-   LSB 1974YH (5) 90   pf/rh   7/ 10                          

  H.F. 691   a hormonal contraceptive patch, but does not include any drug 1   intended to induce an abortion as defined in section 146.1.   2   b. Standing order means a preauthorized medication 3   order with specific instructions from the medical director 4   of the department of health and human services to dispense a   5   medication under clearly defined circumstances.   6   Sec. 4. MEDICAID COVERAGE  SELF-ADMINISTERED HORMONAL 7   CONTRACEPTIVES. Notwithstanding section 514B.32, subsection 8   5, and any other provision of law to the contrary, the 9   department of health and human services shall, contractually 10   and by administrative rules adopted pursuant to chapter 11   17A, require under Medicaid fee-for-service and Medicaid 12   managed care administration, coverage for a self-administered 13   hormonal contraceptive as prescribed by a practitioner as 14   defined in section 155A.3, or as prescribed by standing order 15   and dispensed by a pharmacist pursuant to section 155A.49, 16   including payment for up to an initial twelve-month supply 17   of the self-administered hormonal contraceptive dispensed 18   at one time and for up to a twelve-month supply of the same 19   self-administered hormonal contraceptive subsequently dispensed 20   at one time. 21   EXPLANATION 22   The inclusion of this explanation does not constitute agreement with 23   the explanations substance by the members of the general assembly. 24   This bill relates to the dispensing of self-administered 25   hormonal contraceptives by a pharmacist. The bill 26   defines self-administered hormonal contraceptive as a 27   self-administered hormonal contraceptive that is approved by 28   the United States food and drug administration to prevent 29   pregnancy, including an oral hormonal contraceptive, a hormonal 30   vaginal ring, and a hormonal contraceptive patch, but not 31   including any drug intended to induce an abortion. 32   The bill provides that notwithstanding any provision of law 33   to the contrary, a pharmacist may dispense a self-administered 34   hormonal contraceptive to a patient pursuant to a standing 35   -8-   LSB 1974YH (5) 90   pf/rh   8/ 10           

  H.F. 691   order established by the medical director of the department of 1   health and human services (medical director). For an initial 2   dispensing, a pharmacist may dispense up to a 12-month supply 3   at one time of the self-administered hormonal contraceptive, 4   and for any subsequent dispensing of the same self-administered 5   hormonal contraceptive, a 12-month supply at one time. 6   Additionally, the bill prohibits a pharmacist who dispenses 7   a self-administered hormonal contraceptive in accordance 8   with the bill from requiring any other prescription drug 9   order authorized by a practitioner prior to dispensing the 10   self-administered hormonal contraceptive. 11   The bill authorizes the medical director to establish a 12   standing order authorizing the dispensing of self-administered 13   hormonal contraceptives by any pharmacist who complies with the 14   standing order and retains and submits the patients record to 15   the department of health and human services (HHS). 16   The standing order includes requiring a pharmacist who 17   dispenses a self-administered hormonal contraceptive under 18   the bill to: complete a standardized training program and 19   continuing education requirements related to prescribing the 20   hormonal contraceptives; obtain a completed self-screening risk 21   assessment from each patient and verify the identity of each 22   patient before dispensing the hormonal contraceptives; provide 23   the patient with certain written information; provide the 24   patient with a copy of the record of the pharmacists encounter 25   with the patient; and provide patient counseling. 26   The standing order would prohibit a pharmacist who dispenses 27   hormonal contraceptives under the bill from requiring a 28   patient to schedule an appointment with the pharmacist for 29   the prescribing or dispensing of the hormonal contraceptive; 30   and dispensing the hormonal contraceptives to a patient if 31   the results of the patients self-screening risk assessment 32   indicate it is unsafe for the pharmacist to dispense the 33   hormonal contraceptives to the patient, in which case the 34   pharmacist shall refer the patient to a practitioner. 35   -9-   LSB 1974YH (5) 90   pf/rh   9/ 10  

  H.F. 691   The bill provides immunity for a pharmacist who dispenses a 1   self-administered hormonal contraceptive and for the medical 2   director who establishes a standing order in compliance with 3   the bill from criminal and civil liability arising from any 4   damages caused by the dispensing, administering, or use of a 5   self-administered hormonal contraceptive or the establishment 6   of the standing order provided the pharmacist acts reasonably 7   and in good faith. Additionally, the medical director shall 8   be considered to be acting within the scope of the medical 9   directors office and employment for purposes of Code chapter 10   669 (Iowa tort claims Act) in the establishment of a standing 11   order in compliance with the bill. 12   The bill requires HHS, in collaboration with the boards of 13   pharmacy and medicine, and in consideration of the guidelines 14   established by the American congress of obstetricians and 15   gynecologists, to adopt administrative rules to administer the 16   bill. 17   The bill amends prescription contraceptive coverage 18   provisions to require that a group policy, contract, or plan 19   delivered, issued for delivery, continued, or renewed in the 20   state on or after January 1, 2024, providing for third-party 21   payment or prepayment of health or medical expenses, shall 22   specifically provide for payment of self-administered hormonal 23   contraceptives, prescribed and dispensed as specified in the 24   bill, including those dispensed at one time. 25   The bill also requires HHS to provide prescription 26   contraceptive coverage under the Medicaid program consistent 27   with the coverage under private insurance as provided under the 28   bill. 29   -10-   LSB 1974YH (5) 90   pf/rh   10/ 10